^
Association details:
| Biomarker: | EGFR S492R |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | futuximab/modotuximab (S95026) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer
Excerpt:
In dose-expansion cohorts of 9 and 12 mg/kg of Sym004 weekly, patients with metastatic colorectal cancer and acquired EGFR inhibitor resistance were enrolled;...a partial response was seen in a patient with EGFR(S492R) mutation...
DOI:
10.1158/2159-8290.CD-14-1432
Trial ID:
Source:
Title:
The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer
Excerpt:
Strikingly, in the group of Sym004-treated S492R EGFR-mutant DCR7 cells injected mice, no tumor growth was observed along the whole experiment (Fig. 3B), suggesting that Sym004 is able to induce a profound and sustained tumor regression.
DOI:
10.1158/1078-0432.CCR-15-2400
